Małgorzata Bartkowiak-Emeryk1, Andrzej Emeryk2, Jacek Roliński1, Ewelina Wawryk-Gawda3, Ewa Markut-Miotła2. 1. Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland. 2. Department of Paediatric Pulmonology and Rheumatology, Medical University of Lublin, Lublin, Poland. 3. Department of Paediatric Pulmonology and Rheumatology, Medical University of Lublin, Lublin, Poland. ewelina.wawryk@wp.pl.
Abstract
BACKGROUND:Polyvalent Mechanical Bacterial Lysate (PMBL®) contains antigens of bacteria responsible for respiratory infections. PMBL® has been proven to reduce the number of respiratory infections, and in its use, immunological benefits have been seen in allergic patients. PMBL® activates both innate and specific immune responses. The lysate induces dendritic cells, T and B lymphocytes and IgA secretion, as well as the production of antibodies directed against administered bacterial antigens. Moreover, it increases the response against other bacteria and viruses. The immunologic mechanism of lysate's action is not yet clearly determined. The objective of this study was to assess the effect of PMBL® on T cells in children with allergic asthma. METHODS: This study was a part of the EOLIA study. Herein, 49 children with allergic asthma and house dust mites allergy were included: 21 in PMBL® and 28 in thePlacebo group, both, drug and placebo were administered sublingually. The tests were done at baseline and 12 weeks after the last tablet intake. The lymphocytes CD45+, lymphocytes T CD3+, CD3+CD25+, CD3+CD69+, Th CD3+CD4+, CD4+CD25+, CD4+CD25+ high, CD4+CD69+, Treg CD4+CD25+FOXP3, Tc CD3+CD8+, CD8+CD25+, CD8+CD69+, NK-like T CD3+CD16+CD56+ and NK cellsCD3-CD16+CD56+ were described. RESULTS: At baseline, no significant differences between groups relative to blood count cells were observed, except for eosinophils. After 12 weeks, we observed an increase of T lymphocytes count. In addition, CD4+CD25+FOXP3+, CD8+ and CD3-CD16+CD56+ and (insignificantly) Th count increased. However, CD69+ and CD25+ subset of CD3+ significantly decreased. CONCLUSIONS: The EOLIA study demonstrated that PMBL® administration 10 days per month for 3 months changed the panel of T lymphocytes. Trial registration Clinical Trial Registration: This study was a part of the EOLIA (Efficacy Of mechanical bacterial Lysate In Allergic children), a clinical study NCT02541331. Frederic Durmont, MD Lallemand Pharma International AG. Date of registration 09/08/2013. URL of trial registry record: https://clinicaltrials.gov/ct2/show/study/NCT02541331.
RCT Entities:
BACKGROUND: Polyvalent Mechanical Bacterial Lysate (PMBL®) contains antigens of bacteria responsible for respiratory infections. PMBL® has been proven to reduce the number of respiratory infections, and in its use, immunological benefits have been seen in allergicpatients. PMBL® activates both innate and specific immune responses. The lysate induces dendritic cells, T and B lymphocytes and IgA secretion, as well as the production of antibodies directed against administered bacterial antigens. Moreover, it increases the response against other bacteria and viruses. The immunologic mechanism of lysate's action is not yet clearly determined. The objective of this study was to assess the effect of PMBL® on T cells in children with allergic asthma. METHODS: This study was a part of the EOLIA study. Herein, 49 children with allergic asthma and house dust mitesallergy were included: 21 in PMBL® and 28 in the Placebo group, both, drug and placebo were administered sublingually. The tests were done at baseline and 12 weeks after the last tablet intake. The lymphocytes CD45+, lymphocytes T CD3+, CD3+CD25+, CD3+CD69+, Th CD3+CD4+, CD4+CD25+, CD4+CD25+ high, CD4+CD69+, TregCD4+CD25+FOXP3, Tc CD3+CD8+, CD8+CD25+, CD8+CD69+, NK-like T CD3+CD16+CD56+ and NK cells CD3-CD16+CD56+ were described. RESULTS: At baseline, no significant differences between groups relative to blood count cells were observed, except for eosinophils. After 12 weeks, we observed an increase of T lymphocytes count. In addition, CD4+CD25+FOXP3+, CD8+ and CD3-CD16+CD56+ and (insignificantly) Th count increased. However, CD69+ and CD25+ subset of CD3+ significantly decreased. CONCLUSIONS: The EOLIA study demonstrated that PMBL® administration 10 days per month for 3 months changed the panel of T lymphocytes. Trial registration Clinical Trial Registration: This study was a part of the EOLIA (Efficacy Of mechanical bacterial Lysate In Allergicchildren), a clinical study NCT02541331. Frederic Durmont, MD Lallemand Pharma International AG. Date of registration 09/08/2013. URL of trial registry record: https://clinicaltrials.gov/ct2/show/study/NCT02541331.
Authors: F Braido; G Schenone; E Pallestrini; G Reggiardo; G Cangemi; G W Canonica; G Melioli Journal: J Biol Regul Homeost Agents Date: 2011 Jul-Sep Impact factor: 1.711
Authors: Jaime P Olenec; Woo Kyung Kim; Wai-Ming Lee; Fue Vang; Tressa E Pappas; Lisa E P Salazar; Michael D Evans; Jack Bork; Kathleen Roberg; Robert F Lemanske; James E Gern Journal: J Allergy Clin Immunol Date: 2010-04-14 Impact factor: 10.793
Authors: Michael Schatz; Christine A Sorkness; James T Li; Philip Marcus; John J Murray; Robert A Nathan; Mark Kosinski; Trudy B Pendergraft; Priti Jhingran Journal: J Allergy Clin Immunol Date: 2006-03 Impact factor: 10.793